Zenocutuzumab
Last Updated: 04/28/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 29 publications
Advances in the clinical application of bispecific antibodies in cancer therapy.
Journal: iScience
Published: January 01, 2026
KRAS-Wild Pancreatic Cancer-More Targets than Treatment Possibilities?
Journal: Cancers
Published: October 29, 2025
NRG1 fusion-positive solid tumors: clinical detection, genomic landscape, and real-world data in pancreatic cancer.
Journal: Journal of the National Cancer Institute
Published: October 13, 2025
COLEC12high TAMs Orchestrate Lenvatinib Resistance and Cancer Stemness in HCC via Paracrine NRG1-HER2/HER3 Signaling.
Journal: Clinical and molecular hepatology
Published: September 26, 2025
Characterizing the molecular and clinical implications of NRG1 fusions in NSCLC through integrated RNA and DNA sequencing analysis.
Journal: European journal of medical research
Published: September 16, 2025
Unveiling the Potential of Zenocutuzumab: A Breakthrough in NSCLC and Pancreatic Adenocarcinoma Treatment.
Journal: Oncology (Williston Park, N.Y.)
Published: August 20, 2025
Actionable mutations in pancreatic cancer: where targeted therapies are making a difference.
Journal: BMJ open gastroenterology
Published: May 28, 2025
Bispecific Antibodies in Non-Small Cell Lung Cancer: From Targeted Innovation to Real-World Integration.
Journal: American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting
Published: May 21, 2025
Targeting Tumor Microenvironment-Derived NRG1-HER2/3 Signaling with Zenocutuzumab Restores Sensitivity to AR Inhibition in PTEN Wild-type Prostate Cancer.
Journal: Molecular cancer therapeutics
Published: May 05, 2025
Emerging importance of HER3 in tumorigenesis and cancer therapy.
Journal: Nature reviews. Clinical oncology
Published: February 24, 2025
Zenocutuzumab shows efficacy in NRG1 fusion-positive solid tumours.
Journal: Nature reviews. Clinical oncology
Published: February 20, 2025
Efficacy of Zenocutuzumab in NRG1 Fusion-Positive Cancer.
Journal: The New England journal of medicine
Published: February 05, 2025
Last Updated: 04/28/2026